GeneDx【WGS】銘柄情報

	リアルタイム株価	レベル2
Forex

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

76.00

買値

80.00

売値

80.20

出来高

398,124

76.56 日の範囲 82.78

1.41 52 週間の範囲 89.1099

時価総額

2.088B

前日終値

80.52

始値

82.78

時刻

80.21

最終取引時間

08:20:44

財務取引量

US$ 31,661,923

VWAP

79.5278

平均取引量 (3 か月)

595,535

発行済株式数

27,471,397

配当利回り

PER

-12.41

1 株当たり利益 (EPS)

-6.4

歳入

202.57M

純利益

-175.77M

GeneDx Holdings Corp. is a genomics company. The Company is focused on delivering personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The Companyâ¿¿s segments are GeneDx and Legacy Sema4. The GeneDx segment primarily provides pediatric and ra... GeneDx Holdings Corp. is a genomics company. The Company is focused on delivering personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The Companyâ¿¿s segments are GeneDx and Legacy Sema4. The GeneDx segment primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. GeneDx utilizes an integrated portfolio of laboratory processes, software tools, and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. GeneDx provides a variety of genetic diagnostic tests, screening solutions, and information. The Legacy Sema4 diagnostics segment provides reproductive and womenâ¿¿s health and somatic oncology diagnostic testing and screening products. 詳細を表示

セクター

Blank Checks

業界

Health Services

ウェブサイト

www.genedx.com

本社

Wilmington, Delaware, USA

設立

2020

GeneDx Holdings Corporation is listed in the Blank Checks sector of the ナスダック市場 with ticker WGS. The last closing price for GeneDx was US$80.52. Over the last year, GeneDx shares have traded in a share price range of US$ 1.41 to US$ 89.1099.

GeneDx currently has 27,471,397 shares in issue. The market capitalisation of GeneDx is US$2.21 billion. GeneDx has a price to earnings ratio (PE ratio) of -12.41.

GeneDx to Participate in Upcoming Investor Conference

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in the Piper Sandler 36th Annual...

GeneDx Fuels Rare Disease Drug Discovery with Launch of GeneDx Discover

New Biopharma Solution Aims to Accelerate the Delivery of Precision Medicine to More Patients GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today...

GeneDx Announces Heidi Chen as Chief Legal Officer and Corporate Secretary

Veteran Legal Executive from Zoetis and Pfizer Joins GeneDx Executive Leadership Team to Lead Legal, Compliance and Policy Functions GeneDx (Nasdaq: WGS), a leader in delivering improved health...

New GeneDx Study Reveals Racial Disparities in Genetic Diagnosis Due to Systemic Barriers, Not Diagnostic Yields

Data demonstrates the strength of GeneDx’s diverse database; exome diagnostic rate is high regardless of patient’s ancestral background GeneDx industry leading dataset from 46% non-white...

GeneDx to Highlight Key Research Findings at American Society of Human Genetics (ASHG) Annual Meeting

Data to be presented showcasing GeneDx’s ongoing commitment to spearheading industry-leading research to drive transformational clinical utility GeneDx (Nasdaq: WGS), a leader in delivering...

GeneDx Reports Third Quarter 2024 Financial Results and Business Highlights

Achieved profitability milestone with third quarter adjusted net income1 of $1.2M Reported third quarter 2024 revenues2 of $76.6M with 77% year-over-year growth of exome and genome test...

Groundbreaking GUARDIAN Study Shows Benefits of Adding Genome Sequencing to Newborn Screening; Augments and Improves Standard Newborn Screening

Findings published today in JAMA (Journal of the American Medical Association) reveal limitations of current screening methods and showcase the promise of advanced genomic technology to deliver...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	5.37	7.60300155741	70.63	82.8	68.01	546185	76.23741816	CS
4	-7.6	-9.09090909091	83.6	89.1099	66	664115	76.32054664	CS
12	45.94	152.827677977	30.06	89.1099	28.86	595535	61.63667524	CS
26	54.81	258.659745163	21.19	89.1099	19.54	498280	47.76962593	CS
52	74.49	4933.11258278	1.51	89.1099	1.41	438036	32.2073035	CS
156	65.077	595.779547743	10.923	89.1099	1.16	962086	17.12727618	CS
260	65.077	595.779547743	10.923	89.1099	1.16	962086	17.12727618	CS

出来高
値上がり率
値下がり率

銘柄コード	株価	出来高
BMRABiomerica Inc	US$ 0.4423 (37.32%)	10.41M
ONCOOnconetix Inc	US$ 0.85 (28.40%)	585.22k
ONVOOrganovo Holdings Inc	US$ 0.555 (26.02%)	227.51k
BSLKBolt Projects Holdings Inc	US$ 0.364 (22.97%)	78.44k
PGHLPrimega Group Holdings Ltd	US$ 1.9001 (15.16%)	10.49M
APLTApplied Therapeutics Inc	US$ 1.95 (-77.25%)	9.66M
TOIIWOncology Institute Inc	US$ 0.0135 (-28.57%)	5.82k
CMAXCareMax Inc	US$ 0.3271 (-22.40%)	480k
TCBPTC BioPharm Holdings PLC	US$ 0.50 (-16.67%)	188.99k
PROCProcaps Group SA	US$ 1.80 (-13.88%)	16.97k
CRKNCrown Electrokinetics Corporation	US$ 0.297 (6.41%)	12.89M
IDAIT Stamp Inc	US$ 0.735 (-12.50%)	10.49M
PGHLPrimega Group Holdings Ltd	US$ 1.91 (15.76%)	10.49M
BMRABiomerica Inc	US$ 0.443999 (37.85%)	10.42M
APLTApplied Therapeutics Inc	US$ 1.95 (-77.25%)	9.66M